Drug
PTK787/ZK 222584
PTK787/ZK 222584 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 50.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 3 completed trials
Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
3(50%)
Phase Distribution
Ph phase_1
3
50%
Ph phase_2
3
50%
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
3 of 6 finished
Non-Completion Rate
50.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(3)
Terminated(3)
Detailed Status
Completed3
Terminated3
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (50.0%)
Phase 23 (50.0%)
Trials by Status
completed350%
terminated350%
Recent Activity
0 active trials
Showing 5 of 6
terminatedphase_1
Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00358163
terminatedphase_1
PTK/ZK in Disseminated Malignant Melanoma
NCT00615160
completedphase_2
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
NCT00052013
completedphase_2
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
NCT00053885
terminatedphase_2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
NCT00240162
Clinical Trials (6)
Showing 6 of 6 trials
NCT00358163Phase 1
Trial of PTK787/ZK 222584 Plus Paclitaxel
NCT00615160Phase 1
PTK/ZK in Disseminated Malignant Melanoma
NCT00052013Phase 2
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
NCT00053885Phase 2
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
NCT00240162Phase 2
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
NCT00385853Phase 1
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6